Welcome to our dedicated page for Glaukos news (Ticker: GKOS), a resource for investors and traders seeking the latest updates and insights on Glaukos stock.
Glaukos Corporation (NYSE: GKOS) is an ophthalmic pharmaceutical and medical technology company whose news flow centers on glaucoma, corneal disorders, and retinal diseases. The company’s updates frequently highlight its Micro-Invasive Glaucoma Surgery (MIGS) platform, long-duration intracameral implants, and bio-activated pharmaceutical therapies for chronic eye conditions.
Investors following GKOS news can expect regular announcements on financial performance, including quarterly and annual net sales results, segment trends in glaucoma and corneal health, and updates to revenue guidance ranges. These disclosures are often accompanied by conference call and webcast details, as well as supplemental materials such as quarterly summary documents.
Product and pipeline developments are another major focus of Glaukos news. Recent communications have described the commercial launch activities for iDose TR, a long-duration intracameral procedural pharmaceutical implant for glaucoma, and U.S. FDA approval of Epioxa HD / Epioxa, an incision-free, epithelium-on corneal collagen cross-linking therapy for keratoconus. The company also highlights scientific presentations and posters featuring its technologies at major ophthalmology meetings.
Corporate and operational updates appear in the news flow as well, including participation in healthcare and investor conferences and plans for a new research, development, and manufacturing facility in Huntsville, Alabama. Together, these items provide insight into Glaukos’ commercial execution, research pipeline, manufacturing expansion, and overall strategy in ophthalmic pharmaceuticals and medical technology.
For market participants, the GKOS news page offers a consolidated view of these developments, making it easier to track key milestones in glaucoma devices, corneal cross-linking therapies, and other chronic eye disease initiatives reported by the company.
Glaukos Corporation (NYSE: GKOS), a leader in ophthalmic medical technology, will present its innovative products at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting from April 22-26, 2022, in Washington, D.C. Glaukos is sponsoring an educational symposium titled “Expanding Your Treatment Algorithm: New, Innovative Product Portfolio from Glaukos” on April 22 at 5:30 PM, featuring notable experts. Key presentations will include findings on the Trabecular Micro-Bypass Stent and other advancements in glaucoma and corneal health therapies, enhancing their market presence and potential future growth.
Summary not available.
Glaukos Corporation (NYSE: GKOS) will announce its first quarter 2022 financial results after market close on May 4, 2022. A conference call will follow at 1:30 p.m. PT (4:30 p.m. ET) to discuss the findings. Investors can access the live webcast through the company's website and call in using specific phone numbers for U.S. and international participants. Glaukos specializes in innovative treatments for glaucoma, corneal disorders, and retinal diseases, having introduced Micro-Invasive Glaucoma Surgery (MIGS) in 2012.
Glaukos Corporation (NYSE: GKOS) has announced the initiation of a Phase 2 clinical program for its third-generation iLink™ therapy aimed at treating keratoconus. This innovative therapy utilizes a proprietary system to deliver ultraviolet light for corneal cross-linking, enhancing the strength and shape of the cornea. The Phase 2 study will involve two multi-center, randomized, controlled trials to assess customized versus non-customized treatment patterns and a new bio-activation system. Patient enrollment will occur across the United States, Europe, South America, and Asia, with a follow-up period of six months.
Glaukos Corporation (GKOS) reported its Q4 2021 net sales at $73.2 million, consistent with Q4 2020. Glaucoma and Corneal Health net sales were $57.1 million and $16.2 million, respectively. The gross margin improved to 77% from 73% a year earlier. However, the company faced a net loss of $21.9 million, or ($0.47) per diluted share, worsened from a net loss of $10.6 million in Q4 2020. For the full year, net sales increased by 31% to $294.0 million. The company projects 2022 net sales between $265 million and $275 million.
Glaukos Corporation (NYSE: GKOS) has announced key executive leadership changes effective April 1, 2022, to drive future growth. Joseph Gilliam becomes President and COO, previously CFO since May 2017. Chris Calcaterra transitions to Executive VP, Global Commercial Operations, after serving as COO since February 2017. Alex Thurman is promoted to CFO, having been VP of Finance. Tomas Navratil, Ph.D., takes on the role of Chief Development Officer, focusing on R&D. These promotions aim to align leadership with strategic objectives for transforming chronic eye disease treatments.
Glaukos Corporation (NYSE: GKOS) will announce its fourth quarter and full year 2021 financial results post-market on February 22, 2022. A conference call is scheduled for 1:30 p.m. PST (4:30 p.m. EST) the same day to discuss these results. Investors can access the live webcast via the company’s website. Glaukos specializes in innovative therapies for glaucoma and related ophthalmic disorders, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) and launched multiple devices since 2012.
Glaukos Corporation (NYSE: GKOS) has commenced a Phase 2 clinical trial of GLK-301, targeting Dry Eye Disease (DED). This investigational drug, using Glaukos' innovative iLution platform, is formulated as a cream applied to the eyelids for transdermal delivery of pilocarpine. The trial will assess safety and efficacy across 200 patients over 28 days, followed by a safety follow-up. This development addresses a significant clinical need in the ophthalmic market, as stated by CEO Thomas Burns, emphasizing the potential of the iLution platform in treating chronic eye diseases.
Glaukos Corporation (NYSE: GKOS) has initiated the first patient enrollment in a Phase 2 clinical trial for GLK-302, targeting presbyopia treatment. This investigational drug employs the iLution platform's cream-based drug formulation for transdermal delivery via the eyelid. The trial is designed to assess safety and efficacy across three dosage levels with 120 presbyopic patients expected to participate. The company seeks to address unmet needs for effective, dropless therapies as presbyopia affects millions globally.
Glaukos Corporation (NYSE:GKOS) announced positive outcomes from its Phase 2b clinical trial of the iDose TR implant for glaucoma treatment, showing that approximately 70% of subjects maintained controlled intraocular pressure with fewer topical medications over 36 months. The trial demonstrated an average IOP reduction of 8.3 mmHg and a favorable safety profile, with no significant adverse effects reported. Following these promising results, Glaukos is preparing for a Phase 3 trial, with NDA submission targeted for 2022 and potential FDA approval in 2023.